CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer's disease

Brain Research

Volumn 1251, Issue , 2009, Pages 1-6

  Noguchi Shinohara, Moeko ^a   Tokuda, Takahiko ^b   Yoshita, Mitsuhiro ^a   Kasai, Takashi ^b   Ono, Kenjiro ^a   Nakagawa, Masanori ^b   El Agnaf, Omar M A ^c   Yamada, Masahito ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Alpha synuclein; Dementia with Lewy bodies; Parkinson's disease; Parkinsonism

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ALPHA SYNUCLEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; FEMALE; HEART SCINTISCANNING; HUMAN; LEWY BODY; MALE; PRIORITY JOURNAL;

AGE OF ONSET; AGED; ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; BRAIN; FEMALE; GENOTYPE; HEART; HUMANS; IODINE RADIOISOTOPES; LEWY BODY DISEASE; MALE; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; PREDICTIVE VALUE OF TESTS; SYMPATHETIC FIBERS, POSTGANGLIONIC; TAU PROTEINS;

EID: 58149374375     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2008.11.055     Document Type: Article

References (22)

1. American Psychiatric Association. Diagnostic And Statistical Manual of Mental Disorders. Fourth Edition (1994) American Psychiatric Association, Washington, DC
2. Chapman J., Estupinan J., Asherov A., and Goldfarb L.G. A simple and efficient method for apolipoprotein E genotype determination. Neurology 46 (1996) 1484-1485
3. El-Agnaf O.M., Salem S.A., Paleologou K.E., Curran M.D., Gibson M.J., Court J.A., Schlossmacher M.G., and Allsop D. Detection of oligometric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 20 (2006) 419-425
4. Folstein M., Folstein S.E., and McHugh P.R. "Mini mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12 (1975) 189-198
5. (1-42) and tau levels in CSF. Neurology 52 (1999) 1555-1562
6. Hughes C.P., Berg L., Danziger W.L., Coben L.A., and Martin R.L. A new clinical scale for the staging of dementia. Br. J. Psychiatry 140 (1982) 566-572
7. Kamboh M.I., Ferrel R.E., and Kottke B. Genetic studies of human apolipoproteins V: a novel rapid procedure to screen apolipoprotein E polymorphism. J. Lipid Res. 29 (1998) 1535-1543
8. 42. Arch. Neurol. 60 (2003) 1202-1206
9. McKeith I.G., Galasko D., Kosaka K., Perry E.K., Dickson D.W., Hansen L.A., Salmon D.P., Lowe J., Mirra S.S., Byrne E.J., Lennox G., Quinn N.P., Edwardson J.A., Ince P.G., Bergeron C., Burns A., Miller B.L., Lovestone S., Collerton D., Jansen E.N., Ballard C., de Vos R.A., Wilcock G.K., Jellinger K.A., and Perry R.H. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 47 (1996) 1113-1124
10. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984) 939-944
11. Mollenhauer B., Cepek L., Bibl M., Witfang J., Schulz-Schaeffer W.J., Ciesielczyk B., Neumann M., Steinacker P., Kretzschmar H.A., Poser S., Trenkwalder C., and Otto M. Tau protein, abeta 42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement. Geriatr. Cogn. Disord. 19 (2005) 164-170
12. Mollenhauer B., Cullen V., Kahn I., Krastins B., Outeiro T.F., Pepivani I., Ng J., Schulz-Schaeffer W., Kretzschmar H.A., McLean P.J., Trenkwalder C., Sarracino D.A., Vonsattel J.P., Locascio J.J., El-Agnaf O.M., and Schlossmacher M.G. Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp. Neurol. 213 (2008) 315-325
13. 123I] MIBG) myocardial scintigraphy in differentiating between Alzheimer's disease and dementia with Lewy bodies. Internal. Med. 42 (2003) 686-690
14. Ono K., Noguchi-Shinohara M., Yoshita M., Naiki H., and Yamada M. Cerebrospinal fluid of Alzheimer's disease and dementia with Lewy bodies patients enhances α-synuclein fibril formation in vitro. Exp. Neurol. 203 (2007) 579-583
15. Orimo S., Amino T., Itoh Y., Takahashi A., Kojo T., Uchihara T., Tsuchiya K., Mori F., Wakabayashi K., and Takahashi H. Cardiac sympathetic denervation precedes neuronal loss in the sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol. 109 (2005) 583-588
16. Parnetti L., Lanari A., Amici S., Gallai V., Vanmechelen E., and Hulstaert F. Phospho-tau International Study Group. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies, Phospho-Tau International Study Group. Neuro. Sci. 22 (2001) 77-78
17. Spillantini M.G., Lee V.M.Y., and Trojanowski J.Q. α-Synuclein in Lewy bodies. Nature 388 (1997) 839-840
18. Tokuda T., Salem S.A., Allsop D., Mizuno T., Nakagawa M., Qureshi M.M., Locascio J.J., Schlossmacher M.G., and El-Agnaf O.M.A. Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 349 (2006) 162-166
19. 123I-meta-iodobenzylguanidine (MIBG) uptake in dementia with Lewy bodies: comparison with Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 70 (2001) 781-783
20. Wirths O., Weickert S., Majtenyi K., Havas L., Kahle P.J., Okochi M., Haass C., Multhaup G., Beyreuther K., and Bayer T.A. Lewy body variant of Alzheimer's disease: alpha-synuclein in dystrophic neuritis of A beta plaques. NeuroReport 11 (2000) 3737-3741
21. 123I] MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's-type and dementia with Lewy bodies. J. Neurol. Neurosurg. Psychiatry 71 (2001) 583-588
22. 123I-MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology 66 (2006) 1850-1854